Author

Tu D. L. Thi

Observed names: T. D. Le Thi, Tu Duyen Le Thi, Tu Le Thi

Institution: Novo Nordisk (Denmark)

Observed institutions: Novo Nordisk (Denmark), National University of Malaysia

OpenAlex ID: A5110001248

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

2009 · M. Marre, J. Shaw, et al. · Diabetic Medicine · 822

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

2010 · Lotte Bjerre Knudsen, Lars Wichmann Madsen, et al. · Endocrinology · 698

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

2011 · Laszlo Hegedüs, Alan C. Moses, et al. · The Journal of Clinical Endocrinology & Metabolism · 197

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

2011 · Steen H. Ingwersen, Manoj Khurana, et al. · The Journal of Clinical Pharmacology · 35

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

2010 · Lotte Bjerre Knudsen, Lars Wichmann Madsen, et al. · The Journal of Clinical Endocrinology & Metabolism · 23

Works count: 5

Citation count: 1,775

H-index: 5

I10-index: 5